RBC Capital reiterates Nike stock rating on China headwinds

Nike guided to revenue down in the low single digits (reported) and flat EPS year-over-year for calendar 2026 through fiscal Q2 2027, a outlook that implies roughly a 25% fiscal 2027 EPS downgrade versus Visible Alpha consensus. Q3 results: revenue $11.3bn (flat reported, -3% cc) and EPS $0.35 (beat BTIG $0.26); gross margin 40.2% with a 5ppt hit from unhealthy inventory removal. Shares tumbled ~9% after-hours to $52.82, nearing a 52-week low of $50.95, and several firms cut price targets while many kept Buy/Overweight ratings. Key headwinds cited: Greater China sell-in management/inventory cleanup and mixed channel dynamics despite encouraging North America performance.

Analysis

Nike’s Win Now cleanup in Greater China is doing the heavy lifting for long-term margin quality but is also creating a predictable revenue trough that will cascade upstream: expect 2–4 quarters of lower factory orders and uneven AP/AR timing for key footwear OEMs (Pou Chen-style suppliers) and regional wholesalers. That trade-off—short-term top-line pain for future gross-margin stability—creates a convex payoff where the bulk of upside is realized once channel inventories normalize and wholesale cadence resumes.

Second-order winners include brands and channels able to fill the temporary shelf-space vacuum in China and value footwear suppliers in Southeast Asia that can re-price share quickly; losers are wholesale distributors and any vertically constrained licensees with high fixed-cost footprints. Macro tail-risks that would extend the drawdown are weak Chinese consumption, another promotional cycle in global footwear, or FX pressure compressing already-guided margins; catalysts that would reverse the trend are measured sell-through improvements in Greater China, accelerating DTC conversion in North America, or an outsized gross-margin beat tied to lower markdowns within 3–9 months.

From a positioning perspective, the market is pricing a durable recovery risk premium—quant selling and fund flows can exaggerate near-term downside but also create fertile idiosyncratic entry points. The optimal stance is asymmetric: protect against near-term downside while keeping exposure to a multi-quarter operational rebound; using duration and option structures lets you buy convexity into the mid-term recovery without betting heavily on immediate demand inflection.

Key Decisions for Investors

• NKE — Buy a 9–15 month call spread (long-dated call / sell higher strike call) sized 2–4% of equity book to play the mid-term margin recovery; risk = premium paid, reward = 2–4x if channel normalization and gross-margin tailwinds arrive within 6–12 months. Use spread to cap cost and target break-even at a ~15–30% equity upside.
• NKE — Buy a 3-month put spread (0.5–1% notional) as cheap near-term insurance against continued downside from oversold technicals or a further China guidance miss; limited downside cost protects existing long exposure through the next retail data prints.
• Pair trade — Short NKE equity (or buy 1–2% notional of protective puts) funded by a long allocation to SMCI (2–4% notional) over a 3–9 month horizon: rationale is rotate from cyclical consumer discretionary execution risk into secular data-center/AI upside. Target asymmetric R/R where downside in NKE is limited by the hedge and upside is driven by SMCI’s secular earnings leverage.
• Tactical income — If implied volatility spikes around near-term retail cadence/events, consider selling a tight, short-dated call spread on NKE (4–6 week) for income sized small (<=1% notional), capturing IV premium while keeping downside capped; avoid if you lack conviction on timing of inventory normalization.